Role and potential of 18F-fluorodeoxyglucose-positron emission tomography-computed tomography in large-vessel vasculitis: a comprehensive review
- PMID: 39170047
- PMCID: PMC11335723
- DOI: 10.3389/fmed.2024.1432865
Role and potential of 18F-fluorodeoxyglucose-positron emission tomography-computed tomography in large-vessel vasculitis: a comprehensive review
Abstract
Large-vessel vasculitis (LVV) is a group of diseases characterized by inflammation of the aorta and its main branches, which includes giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and Takayasu's arteritis (TAK). These conditions pose significant diagnostic and management challenges due to their diverse clinical presentations and potential for serious complications. 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) has emerged as a valuable imaging modality for the diagnosis and monitoring of LVV, offering insights into disease activity, extent, and response to treatment. 18F-FDG-PET-CT plays a crucial role in the diagnosis and management of LVV by allowing to visualize vessel involvement, assess disease activity, and guide treatment decisions. Studies have demonstrated the utility of 18F-FDG-PET-CT in distinguishing between LVV subtypes, evaluating disease distribution, and detecting extracranial involvement in patients with cranial GCA or PMR phenotypes. Additionally, 18F-FDG-PET-CT has shown promising utility in predicting clinical outcomes and assessing treatment response, based on the correlation between reductions in FDG uptake and improved disease control. Future research should focus on further refining PET-CT techniques, exploring their utility in monitoring treatment response, and investigating novel imaging modalities such as PET-MRI for enhanced diagnostic accuracy in LVV. Overall, 18F-FDG-PET-CT represents a valuable tool in the multidisciplinary management of LVV, facilitating timely diagnosis and personalized treatment strategies to improve patient outcomes.
Keywords: PET-CT; Takayasu’s arteritis; giant cell arteritis; large-vessel vasculitis; polymyalgia rheumatica.
Copyright © 2024 Collada-Carrasco, Gómez-León, Castillo-Morales, Lumbreras-Fernández, Castañeda and Rodríguez-Laval.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Role of 18F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica.J Nucl Med. 2023 Apr;64(4):515-521. doi: 10.2967/jnumed.122.265016. J Nucl Med. 2023. PMID: 37011940
-
Positron Emission Computed Tomography Spectrum of Large Vessel Vasculitis in a Tertiary Center: Differences in 18F-fluorodeoxyglucose Uptake between Large Vessel Vasculitis with Predominant Cranial and Extracranial Giant Cell Arteritis Phenotypes.J Clin Med. 2023 Sep 24;12(19):6164. doi: 10.3390/jcm12196164. J Clin Med. 2023. PMID: 37834808 Free PMC article.
-
(18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica.Rev Esp Med Nucl Imagen Mol. 2015 Sep-Oct;34(5):275-81. doi: 10.1016/j.remn.2015.05.011. Epub 2015 Jul 6. Rev Esp Med Nucl Imagen Mol. 2015. PMID: 26159505 Clinical Trial.
-
The utility of 18F-FDG-PET/CT in detecting extracranial large vessel vasculitis in rheumatic polymyalgia or giant cell arteritis. A systematic review and meta-analysis.Rev Clin Esp (Barc). 2024 Aug-Sep;224(7):445-456. doi: 10.1016/j.rceng.2024.06.005. Epub 2024 Jun 7. Rev Clin Esp (Barc). 2024. PMID: 38852739
-
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC.Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1250-1269. doi: 10.1007/s00259-018-3973-8. Epub 2018 Apr 11. Eur J Nucl Med Mol Imaging. 2018. PMID: 29637252 Free PMC article. Review.
Cited by
-
Association of PET vascular activity score with Takayasu's arteritis angiographic progression.Eur J Nucl Med Mol Imaging. 2025 May 28. doi: 10.1007/s00259-025-07348-2. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 40434493
-
18F-Fluorodeoxyglucose Imaging for Assessing Cardiovascular Inflammation.Diagnostics (Basel). 2025 Feb 27;15(5):573. doi: 10.3390/diagnostics15050573. Diagnostics (Basel). 2025. PMID: 40075822 Free PMC article. Review.
References
-
- González-Gay MA, García-Porrúa C. Epidemiology of the vasculitides. Rheum Dis Clin N Am. (2001) 27:729–49. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous